RVX-208 Brings 77% Relative Risk Reduction Of Major Adverse Cardiovascular Events For Diabetes Mellitus Patients
Wednesday, September 10, 2014 - 07:10
in Health & Medicine
In an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix, disclosed that patients with cardiovascular disease (CVD) arising from atherosclerosis when given RVX-208 had a 55% (p=0.02) relative risk reduction (RRR) in Major Adverse Cardiovascular Events (MACE). read more